

《子宮頸癌抗癌藥物治療指引》

115 年版與上一版差異

114 年版 修訂日 114/01/22

CCRT

Chemotherapy Regimens for Recurrent or Metastatic Cervical Cancer

115 年版 修訂日 114/12/17

Chemoradiation

■ 新增 Paclitaxel + Carboplatin

Chemotherapy Regimens for Recurrent or Metastatic Cervical Cancer
Second-line therapy

■ 新增

- Neratinib
- Fam-trastuzumab deruxtecan
- Selpercatinib

《子宮頸癌抗癌藥物治療指引》

Neoadjuvant Chemotherapy of Cervical Cancer

POB

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	50	≥ 2 hrs	d1	Q10D	3	4, 5
Vincristine	1 (Max 2 mg)	10 mins	d1	Q10D	3	
Bleomycin	25	≥ 90 mins	d1-3	Q10D	3	

Paclitaxel + Cisplatin

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	135	≥ 3 hrs	d1	Q3W	6	6
Cisplatin	50	≥ 2 hrs	d1	Q3W	6	

Adjuvant Chemotherapy

Paclitaxel + Cisplatin

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	135	≥ 3 hrs	d1	Q3W	6	6, 7
Cisplatin	50	≥ 2 hrs	d1	Q3W	6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	175	≥ 3 hrs	d1	Q3W	6	10
Cisplatin	50	≥ 2 hrs	d1	Q3W	6	

POB

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	50	≥ 2 hrs	d1	Q10D	3	4, 5
Vincristine	1 (Max 2 mg)	10 mins	d1	Q10D	3	
Bleomycin	25	≥ 90 mins	d1-3	Q10D	3	

Cisplatin + Topotecan

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	50	≥ 2 hrs	d1	Q3W	6	8
Topotecan	0.75	10 mins	d1-3	Q3W	6	

Cisplatin + Gemcitabine

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	30	≥ 2 hrs	d1, 8	Q4W		9
Gemcitabine	800	30 mins	d1, 8	Q4W		

Chemoradiation

Cisplatin

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	40*	≥ 2 hrs	d1	QW	6	1, 2, 3

*Max weekly dose: 70 mg

Pembrolizumab + Cisplatin

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W	5-6	18
Cisplatin	40	≥ 2 hrs	d1	QW	5-6	
Followed by Pembrolizumab	400 mg	≥ 30 mins	d1	Q6W	15	

Category 1: FIGO 2014 Stage III-IVA ; category 2B: FIGO 2018 stage III-IVA

Pembrolizumab + Carboplatin

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W	5-6	18
Carboplatin	AUC 2	1 hr	d1	QW	5-6	
Followed by Pembrolizumab	400 mg	≥ 30 mins	d1	Q6W	15	

Category 1: FIGO 2014 Stage III-IVA ; category 2B: FIGO 2018 stage III-IVA

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Capecitabine	300 mg/day PO		d1-14	Q4W	2	14
Mitomycin C	10	5-10 mins	d1	Q4W	2	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	300	30 mins	d1	QW		15

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	40 or 60	≥ 1 hr	d1	QW		16, 17

Induction therapy (followed by chemoradiation)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	80	≥ 1 hr	d1	QW	6	19
Carboplatin	2AUC	≥ 30 mins	d1	QW	6	

參考文獻

1. Gaffney DK, Erickson-Wittmann BA, Jhingran A, et al. ACR Appropriateness Criteria(R) on Advanced Cervical Cancer Expert Panel on Radiation Oncology-Gynecology. Int J Radiat Oncol Biol Phys 2011;81:609-614.
2. Monk BJ, Tewari KS, Koh W-J. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Oncol 2007;25:2952-2965.
3. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999;340:1154-1161.
4. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340:1137-1143.
5. Peters WA, Liu PY, Barrett RJ, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000;18:1606-1613.
6. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999;17:1339-1348.
7. Sardi LE, Giaroli A, Sananes C, et al. Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy

- in stage Ib squamous carcinoma of the cervix: the final results, *Gynecol Oncol* 1997;67:61-9.
8. Chang TC, Lai CH, Hong JH, Hsueh S, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer.
 9. Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol*.2009;27(28):4649–4655.
 10. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. *J Clin Oncol*.2004;22(15):3113–3119.
 11. Long HJ 3rd, Bundy BN, Grendys EC Jr, et al; Gynecologic Oncology Group Study. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. *J Clin Oncol*. 2005; 23:4626–4633.
 12. Brewer CA, Blessing JA, Nagourney RA, et al. Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. *Gynecol Oncol*. 2006;100:385–388.
 13. The ICON and AGO Collaborators, Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial, *Lancet*. 2003;361:2099-106.
 14. Lorvidhaya V, Chitapanaarux I, Sangruchi S, et al. Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial. *Int J Radiat Oncol Biol Phys*. 2003;55:1226-1232.
 15. Pattaranutaporn P, Thirapakawong C, Chansilpa Y, et al. Phase II study of concurrent gemcitabine and radiotherapy in locally advanced stage IIIB cervical carcinoma. *Gynecol Oncol* 2001;81:404-407.
 16. Candelaria M, Garcia-Aria A, Cetina L, et al., Radiosensitizers in cervical cancer. Cisplatin and beyond. *Radiat Oncol* 2006;1:15.
 17. Cerrotta A, Gardan G, Raspagliesi F, et al., Concurrent radiotherapy and weekly paclitaxel for locally advanced or recurrent squamous cell carcinoma of the uterine cervix. A pilot study with intensification of dose. *Eur J Gynaecol Oncol* 2002;23:115-119.

18. Lorusso D, Xiang Y, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, highrisk, locally advanced cervical cancer (ENGOT-cx11/ GOG-3047/KEYNOTE-A18): a randomised, doubleblind, phase 3 clinical trial. Lancet 2024;403:1341-1350.
19. McCormack M, Eminowicz G, Gallardo D, et al. Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial. Lancet. 2024;404(10462):1525-1535.

Chemotherapy Regimens for Recurrent or Metastatic Cervical Cancer

First-line therapy

For PD-L1 positive

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W		9
Bevacizumab	15 mg/kg	≥ 90 mins	d1	Q3W	6	
Paclitaxel	135 or 175	≥ 3 hrs	d1	Q3W	6	
Cisplatin	50	≥ 2 hrs	d1	Q3W	6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W		9
Bevacizumab	15 mg/kg	≥ 90 mins	d1	Q3W	6	
Paclitaxel	135 or 175	≥ 3 hrs	d1	Q3W	6	
Carboplatin	AUC 5	1 hr	d1	Q3W	6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W		9
Bevacizumab	15 mg/kg	≥ 90 mins	d1	Q3W	6	
Paclitaxel	135 or 175	≥ 3 hrs	d1	Q3W	6	
Carboplatin	AUC 5	1 hr	d1	Q3W	6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Atezolizumab	1200 mg	1 hr	d1	Q3W		16
Bevacizumab	15 mg/kg	≥ 90 mins	d1	Q3W		
Paclitaxel	135 or 175	≥ 3 hrs	d1	Q3W	6+	
Cisplatin	50	≥ 2 hrs	d1	Q3W	6+	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Atezolizumab	1200 mg	1 hr	d1	Q3W		16
Bevacizumab	15 mg/kg	≥ 90 mins	d1	Q3W		
Carboplatin	AUC 5	1 hr	d1	Q3W	6+	
Paclitaxel	135 or 175	≥ 3 hrs	d1	Q3W	6+	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Bevacizumab	15 mg/kg	≥ 90 mins	d1	Q3W	6	1-3
Paclitaxel	135 or 175	≥ 3 hrs	d1	Q3W	6	
Cisplatin	50	≥ 2 hrs	d1	Q3W	6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Bevacizumab	15 mg/kg	≥ 90 mins	d1	Q3W	6	2, 3
Carboplatin	AUC 5	1 hr	d1	Q3W	6	
Paclitaxel	135 or 175	≥ 3 hrs	d1	Q3W	6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Bevacizumab	15 mg/kg	≥ 90 mins	d1	Q3W		1
Paclitaxel	175	≥ 3 hrs	d1	Q3W		
Topotecan	0.75	1 hr	d1-3	Q3W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	175	≥ 3 hrs	d1	Q3W	Max 6	4, 5
Carboplatin	AUC 5	1 hr	d1	Q3W	Max 6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	50	≥ 2 hrs	d1	Q3W	Max 6	6
Topotecan	0.75	1 hr	d1	Q3W	Max 6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	50	≥ 2 hrs	d1	Q3W	6	3

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	400	1 hr	d1	Q4W		7

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	250	≥ 4 hrs	d1	Q3W		8

Second-line therapy

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Nivolumab	240 mg	≥ 30 mins	d1	Q2W		10

PD-L1-positive tumors

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W	35	11

TMB-H tumors or PD-L1-positive or MSI-H/dMMR tumors

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Nivolumab	240 mg	≥ 30 mins	d1	Q2W	up to 2years	12
Ipilimumab	1 mg/kg	≥ 30 mins	d1	Q6W	up to 2years	

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Neratinib	240 mg		QD		13

HER-2 mutant

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Fam-trastuzumab deruxtecan	5.4 mg/kg	90 mins	d1	Q3W		14

HER2-positive tumors (IHC 3+ or 2+)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Selpercatinib	160mg PO		BID		15	

RET gene fusion-positive tumors

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Larotrectinib	100mg PO		BID		16	

NTRK gene fusion-positive tumors

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Entrectinib	600mg PO		QD		17	

NTRK gene fusion-positive tumors

參考文獻

1. Tewari KS1, Sill MW, Long HJ 3rd, et al. Improved Survival with Bevacizumab in Advanced Cervical Cancer. N Engl J Med. 2014 Feb 20; 370(8):734-43
2. Monk BJ, Sill MW, McMeekin DS, et al. Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 2009;27:4649-4655.
3. Moore DH, Blessing JA, McQuellon RP, et al. Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study. J Clin Oncol

- 2004;22:3113-3119.
4. Moore KN, Herzog TJ, Lewin S, et al. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. *Gynecol Oncol* 2007;105:299-303.
5. Kitagawa R, Katsumata N, Shibata T, et al. A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVb, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study (JCOG0505)[abstract]. *J Clin Oncol* 2012;30(Suppl 15):Abstract 5006.
6. Long HJ, 3rd, Bundy BN, Grendys EC, Jr., et al. Randomized Phase III Trial of Cisplatin With or Without Topotecan in Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study. *J Clin Oncol* 2005;23:4626-4633.
7. Weiss GR, Green S, Hannigan EV, et al. A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: A Southwest Oncology Group Study. *Gynecol Oncol* 1990;39:332-336.
8. Kudelka AP, Winn R, Edwards CL, et al. An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. *Anticancer Drugs* 1997;8:657-661.
9. Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. *N Engl J Med*. 2021.
10. Naumann RW, Hollebecque A, Meyer T, et al. Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial. *J Clin Oncol*. 2019;37:2825-2834.
11. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase 2 KEYNOTE-158 study. *J Clin Oncol* 2020;38:1-10.
12. Schenker M, Burotto M, Richardet M, et al. Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden. *J Immunother Cancer* 2024;12:e008872.
13. Friedman CF, D'Souza A, Bello Roufai D, et al. Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial. *Gynecol Oncol*. 2024;181:162-169. doi:10.1016/j.ygyno.2023.12.004

14. Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: DESTINYPanTumor02 Phase II trial. *J Clin Oncol* 2024;42:47-58
15. Subbiah V, Wolf J, Konda B, Kang H, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. *Lancet Oncol.* 2022 Oct;23(10):1261-1273.
16. Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. *Lancet Oncol.* 2020 Apr;21(4):531-540.
17. Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. *Lancet Oncol.* 2020 Feb;21(2):271-282.

《子宮內膜癌抗癌藥物治療指引》

115 年版與上一版差異

114 年版 修訂日 114/01/07	115 年版 修訂日 114/12/17
Primary or Adjuvant Therapy Chemoradiation Therapy	Primary or Adjuvant Therapy Chemoradiation Therapy ■ 刪除 Capecitabine + Mitomycin ■ 刪除 Gemcitabine ■ 刪除 Paclitaxel Adjuvant therapy ■ 新增 Carboplatin + Paclitaxel + Bevacizumab ■ 新增 Carboplatin + Paclitaxel + Durvalumab + Olaparib
Adjuvant Chemoradiation (Uterine-Confined Disease)	■ 刪除 Adjuvant Chemoradiation (Uterine-Confined Disease)

114 年版 修訂日 114/01/07

Systemic Therapy for Recurrent, Metastatic or High-Risk Disease
Hormone Therapy

1st line Chemotherapy Regimens

2nd line Chemotherapy Regimens

115 年版 修訂日 114/12/17

Systemic Therapy for Recurrent, Metastatic or High-Risk Disease
Hormone Therapy

■ 新增明細

1st line Chemotherapy Regimens

■ 新增 Carboplatin + Paclitaxel + Durvalumab + Olaparib

2nd line Chemotherapy Regimens

■ 新增 Gemcitabine

■ 新增 Lenvatinib

■ 新增 Avelumab + Axitinib

■ 新增 Nivolumab + Ipilimumab

■ 新增 Fam-trastuzumab deruxtecan

■ 新增 Selpercatinib

■ 新增 Larotrectinib

■ 新增 Entrectinib

《 子宮內膜癌抗癌藥物治療指引 》

Primary or Adjuvant Therapy (Stage I–IV) Chemoradiation Therapy

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	50 with RT	≥ 2 hrs	d1	Q3W	2	1
Followed by (interval 28 days)						
Carboplatin	AUC 5	≥ 1 hr	d1	Q3W	4	
Paclitaxel	175	≥ 3 hrs	d1	Q3W	4	

Adjuvant therapy

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	175	≥ 3 hrs	d1	Q3W	7	1
Carboplatin	AUC 6	≥ 1 hr	d1	Q3W	7	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Doxorubicin	50	≥ 30 mins	d1	Q3W		2
Cisplatin	50	≥ 2 hrs	d1	Q3W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	135 or 175	≥ 3 hrs	d1	Q3W	6	3
Carboplatin	AUC 5-6	≥ 1 hr	d1	Q3W	6	

Carboplatin + Paclitaxel + Pembrolizumab (for stage III–IV tumors, except for carcinosarcoma)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W	6	4
Carboplatin	AUC 5	≥ 1 hr	d1	Q3W	6	
Paclitaxel	175	≥ 3 hrs	d1	Q3W	6	
Followed by Pembrolizumab	400 mg	≥ 30 mins	d1	Q6W	14	

Carboplatin + Paclitaxel + Trastuzumab (for stage III/IV HER2-positive uterine serous carcinoma or carcinosarcoma)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Trastuzumab	8 → 6	90 → 30 mins	d1	Q3W		5
Carboplatin	AUC 5	≥ 1 hr	d1	Q3W		
Paclitaxel	175	≥ 3 hrs	d1	Q3W		

Carboplatin + Paclitaxel + Durvalumab (for stage III–IV dMMR tumors only)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Durvalumab	1120 mg	1 hr	d1	Q3W		6
Carboplatin	AUC 5 or 6	≥ 1 hr	d1	Q3W		
Paclitaxel	175	≥ 3 hrs	d1	Q3W		
Followed by Durvalumab	1500 mg	1 hr	d1	Q4W		

Carboplatin + Paclitaxel + Bevacizumab(for stage III-IV with measurable disease)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Bevacizumab	15 mg/kg	90 mins	d1	Q3W	6	7
Carboplatin	AUC 5	≥ 1 hr	d1	Q3W	6	
Paclitaxel	175	≥ 3 hrs	d1	Q3W	6	
Followed by						
Bevacizumab	15 mg/kg	90 mins	d1	Q3W		

Carboplatin + Paclitaxel + Durvalumab + Olaparib (for stage III-IV pMMR tumors)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Durvalumab	1120 mg	1 hr	d1	Q3W	6	8
Carboplatin	AUC 5 or 6	≥ 1 hr	d1	Q3W	6	
Paclitaxel	175	≥ 3 hrs	d1	Q3W	6	
Followed by						
Durvalumab	1500 mg	1 hr	d1	Q4W		
Olaparib	300 mg PO			BID		

參考文獻

1. de Boer SM, Powell ME, Mileschkin L, et al. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 2016;17:1114-1126
2. Hogberg T, Signorelli M, de Oliveira CF, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer-

- results from two randomised studies. Eur J Cancer 2010;46:2422-2431.
3. Thigpen JT, Blessing JA, Lagasse LD. Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 1989;33:68-70.
 4. Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med 2023;388:2159-2170
 5. Amanda N. Fader, Dana M. Roque, et al. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. J Clin Oncol. 2018;27:JCO2017765966.
 6. Westin SN, Moore K, Chon HS, et al. Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: The Phase III DUO -E trial. J Clin Oncol. 2023;42:283-299.
 7. Rose PG, Ali S, Moslemi-Kebria M, Simpkins F. Paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma. Int J Gynecol Cancer 2017;27:452-458.
 8. Westin SN, Moore K, Chon HS, et al. Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: The phase III DUO-E trial. J Clin Oncol 2024;42:283-299.

Systemic Therapy for Recurrent, Metastatic or High-Risk Disease

Hormone Therapy

Megestrol acetate and Tamoxifen alternating

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Megestrol acetate	80 mg PO BID	d1-21	Q6W		1
Tamoxifen	20 mg PO BID	d22-42	Q6W		

Everolimus and Letrozole

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Everolimus	10 mg PO QD				2
Letrozole	2.5 mg PO QD				

Medroxyprogesterone acetate and Tamoxifen alternating

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Tamoxifen	20 mg PO BID	d1-7	Q2W		3
Medroxyprogesterone acetate	200 mg PO QD	d8-14	Q2W		

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Tamoxifen	20 mg PO BID	d1-7	Q2W		4
Medroxyprogesterone acetate	500 mg PO QD	d8-14	Q2W		

Medroxyprogesterone acetate

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Medroxyprogesterone acetate	500-1000 mg IM*	d1	QW		5

*If improvement occurs within a few weeks or months, doses as low as 400 mg/month may maintain patients who have stable disease

Megestrol acetate

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Megestrol acetate	40-320 mg/day PO		BID-QID		6

Anastrozole

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Anastrozole	1 mg PO		QD	At least 28 days	7

Letrozole

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Letrozole	2.5 mg PO		QD		8

Examestane

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Examestane	25 mg PO		QD		9

Tamoxifen

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Tamoxifen	20 mg PO BID				10

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
fulvestrant	250 mg IM	d1	Q4W	at least 12 weeks	11

For ER-positive tumors

Letrozole + Ribociclib

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Letrozole	2.5 mg PO		QD		12
Ribociclib	400 mg PO		QD		

Letrozole + Abemaciclib

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Letrozole	2.5 mg PO		QD		13
Abemaciclib	150 mg PO		BID		

1st line Chemotherapy Regimens

Multi-agent chemotherapy regimens preferred, if tolerated

Carboplatin + Paclitaxel + Pembrolizumab (for stage III–IV tumors, except for carcinosarcoma)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W	6	14
Carboplatin	AUC 5	≥ 1 hr	d1	Q3W	6	
Paclitaxel	175	≥ 3 hrs	d1	Q3W	6	
Followed by Pembrolizumab	400 mg	≥ 30 mins	d1	Q6W	14	

Carboplatin + Paclitaxel + Durvalumab (for dMMR tumors only)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Durvalumab	1120 mg	1 hr	d1	Q3W	6	15
Carboplatin	AUC 5 or 6	≥ 1 hr	d1	Q3W	6	
Paclitaxel	175	≥ 3 hrs	d1	Q3W	6	
Followed by Durvalumab	1500 mg	1 hr	d1	Q4W		

Paclitaxel + Carboplatin

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 6	≥ 1 hr	d1	Q3W	7	16
Paclitaxel	175	≥ 3 hrs	d1	Q3W	7	

Doxorubicin + Cisplatin + Paclitaxel

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Doxorubicin	45	≥ 30 mins	d1	Q3W	6	16, 17
Cisplatin	50	≥ 2 hrs	d1	Q3W	6	
Paclitaxel	160	≥ 3 hrs	d2	Q3W	6	

Paclitaxel + Cisplatin

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	135 or 175	≥ 3 hrs	d1	Q3W	6	18
Cisplatin	50	≥ 2 hrs	d1	Q3W	6	

Ifosfamide + Paclitaxel (for carcinosarcoma)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	135	≥ 3 hrs	d1	Q3W	Max 8	19
Ifosfamide	1600 (1200 with RT)	≥ 4 hrs	d1-3	Q3W	Max 8	

Ifosfamide + Cisplatin (for carcinosarcoma)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Ifosfamide	1500	≥ 4 hrs	d1-5	Q3W	3	20
Cisplatin	20	≥ 1 hr	d1-5	Q3W	3	

Carboplatin + Paclitaxel + Bevacizumab

藥品名*	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Bevacizumab	15 mg/kg	≥ 1 hr	d1	Q3W	16	21
Carboplatin	AUC 5	≥ 1 hr	d1	Q3W	6	
Paclitaxel	175	≥ 3 hrs	d1	Q3W	6	

Carboplatin + Paclitaxel + Trastuzumab

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Trastuzumab	8 → 6 mg/kg	90 → 30 mins	d1	Q3W		21
Carboplatin	AUC 5	≥ 1 hr	d1	Q3W		
Paclitaxel	175	≥ 3 hrs	d1	Q3W		

Carboplatin + Docetaxel

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 6	≥ 1 hr	d1	Q3W		22
Docetaxel	75	1 hr	d1	Q3W		

Pembrolizumab(for TMB-H or MSI-H/dMMR tumors.)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W		34

Lenvatinib + Pembrolizumab((MMR-proficient (pMMR) tumors))

藥品名*	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Lenvatinib	20 mg QD PO					23
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W		

Carboplatin/Paclitaxel/Durvalumab + Durvalumab/Olaparib (MMR-proficient (pMMR) tumors)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Durvalumab	1120mg	1 hr	d1	Q3W	6	15
Carboplatin	AUC 5 or 6	≥ 1 hr	d1	Q3W	6	
Paclitaxel	175	≥ 3 hrs	d1	Q3W	6	
Followed by						
Durvalumab	1500mg	1 hr	d1	Q4W		
Olaparib	300mg PO			BID		

2nd line Chemotherapy Regimens

Single Agents

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Bevacizumab	15 mg/kg	≥ 1 hr	d1	Q3W		24

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	50-100	2-4 hrs	d1	Q3W		24, 25

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 4-6	≥ 1 hr	d1	Q3W		24

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Topotecan	0.5-1.5	1 hr	d1-5	Q3W		16, 26

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Topotecan	1.5	1 hr	d1-5	Q3W		26

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Doxorubicin	50-60	≥ 30 mins	d1	Q3W		24

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Lipo-Doxorubicin	50	≥ 2 hrs	d1	Q4W		27

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	250	≥ 3 hrs	d1	Q3W		24

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Temsirolimus	25 mg	30-60 mins	d1	QW		32

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab*	200 mg	≥ 30 mins	d1	Q3W		29

*for MSI-H/ dMMR tumors

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Nivolumab	3 mg/kg	≥ 30 mins	d1	Q2W		30
followed by Nivolumab	480 mg	≥ 30 mins	d1	Q4W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Avelumab*	1500 mg	1 hr	d1	Q4W		31

*for MSI-H/ dMMR tumors

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cabozantinib	60 mg PO		QD			32

Ifosfamide (for carcinosarcoma)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Ifosfamide	1200-2000*	≥ 4 hrs	d1	Q3W	8	33

*The starting dose was 1.2 g/m² for patients who had received prior RT.

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	800	30 mins	d1, 8	Q3W		35

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Lenvatinib	24mg		QD			36

Useful in Certain Circumstances (Biomarker-directed therapy)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Avelumab	800 mg	1 hr	d1,8	Q4W		37
Axitinib	5mg PO			BID		

for pMMR tumors

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Nivolumab	240mg	≥ 30 mins	d1	Q2W	Up to 2 years	38
Ipilimumab	1mg/kg	≥ 30 mins	d1	Q6W	Up to 2 years	

TMB-H tumor

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Fam-trastuzumab deruxtecan-nxki	5.4mg/kg	90 mins	d1	Q3W		39

HER2-positive tumors (IHC 3+ or 2+)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Fam-trastuzumab deruxtecan-nxki	5.4mg/kg	90 mins	d1	Q3W		40

HER2-positive tumors (IHC 1+, 2+ or 3+) (for carcinosarcoma)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Selpercatinib	160mg PO		BID		41

RET gene fusion-positive tumors

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Larotrectinib	100mg PO		BID		42

NTRK gene fusion-positive tumors

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Entrectinib	600mg PO		QD		43

RET gene fusion-positive tumors

參考文獻

1. Fiorica JV, Brunetto VL, Hanjani P, Lentz SS, Mannel R, Andersen W; Gynecologic Oncology Group study. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004 Jan;92(1):10-4. doi: 10.1016/j.ygyno.2003.11.008. PMID: 14751131.
2. Slomovitz BM, Filiaci VL, Walker JL, Taub MC, Finkelstein KA, Moroney JW, Fleury AC, Muller CY, Holman LL,

- Copeland LJ, Miller DS, Coleman RL. A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study. *Gynecol Oncol*. 2022 Mar;164(3):481-491. doi: 10.1016/j.ygyno.2021.12.031. Epub 2022 Jan 19. PMID: 35063278.
3. Whitney CW, Brunetto VL, Zaino RJ, et al. Gynecologic Oncology Group study. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol*. 2004 Jan;92(1):4-9. doi: 10.1016/j.ygyno.2003.09.018. PMID: 14751130.
4. Beltrán M, Alonso MC, Ojeda MB, et al. Alternating sequential endocrine therapy: tamoxifen and medroxyprogesterone acetate versus tamoxifen in postmenopausal advanced breast cancer patients. *Ann Oncol*. 1991 Jul;2(7):495-9. doi: 10.1093/oxfordjournals.annonc.a057999. PMID: 1832944.
5. Product Information: Depo-Provera(R) intramuscular injection suspension, medroxyprogesterone acetate intramuscular injection suspension. Pharmacia and Upjohn Co (per FDA), New York, NY, 2017.
6. Product Information: megestrol acetate oral tablets, megestrol acetate oral tablets. West-Ward Pharmaceuticals Corp. (per DailyMed), Eatontown, NJ, 2016.
7. Mileskshin L, Edmondson R, O'Connell RL, et al. PARAGON study group. Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903. *Gynecol Oncol*. 2019 Jul;154(1):29-37. doi: 10.1016/j.ygyno.2019.05.007. Epub 2019 May 23. PMID: 31130288.
8. Ma BB, Oza A, Eisenhauer E, et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers--a study of the National Cancer Institute of Canada Clinical Trials Group. *Int J Gynecol Cancer*. 2004 Jul-Aug;14(4):650-8. doi: 10.1111/j.1048-891X.2004.14419.x. PMID: 15304161.
9. Lindemann K, Malander S, Christensen RD, et al. Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO). *BMC Cancer*. 2014 Feb 5;14:68. doi: 10.1186/1471-2407-14-68. PMID: 24498853; PMCID: PMC3924910.
10. Thigpen T, Brady MF, Homesley HD, et al: Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol* 2001; 19:364-367.
11. Emons G, Günthert A, Thiel FC, Camara O, et al. Phase II study of fulvestrant 250 mg/month in patients with recurrent

- or metastatic endometrial cancer: a study of the Arbeitsgemeinschaft Gynäkologische Onkologie. *Gynecol Oncol*. 2013 Jun;129(3):495-9. doi: 10.1016/j.ygyno.2013.02.039. Epub 2013 Mar 13. PMID: 23500091.
12. Colon-Otero G, Zanfagnin V, et al. Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers. *ESMO Open*. 2020 Oct;5(5):e000926. doi: 10.1136/esmoopen-2020-000926. PMID: 33109627; PMCID: PMC7592247.
13. Konstantinopoulos PA, Lee EK, Xiong N, et al. A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer. *J Clin Oncol*. 2023 Jan 20;41(3):599-608. doi: 10.1200/JCO.22.00628. Epub 2022 Sep 29. PMID: 36174113.
14. Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. *N Engl J Med* 2023;388:2159-2170
15. Westin SN, Moore K, Chon HS, et al. Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: The Phase III DUO -E trial. *J Clin Oncol*. 2023;42:283-299.
16. Miller D, Filiaci V, Fleming G, et al. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study [abstract]. *Gynecol Oncol* 2012;125:771.
17. Homesley HD, Filiaci V, Gibbons SK, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. *Gynecol Oncol* 2009;112:543-552.
18. Thigpen JT, Blessing JA, Lagasse LD. Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol*. 1989;33:68-70.
19. Homesley HD, Filiaci V, Markman M, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. *J Clin Oncol* 2007;25:526-531.
20. Sutton G, Kauderer J, Carson LF, et al. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. *Gynecol Oncol* 2005;96:630-634.
21. Gil Shechter-Maor; Ilan Bruchim; Zipi Ben-Harim, et al. Combined Chemotherapy Regimen of Carboplatin and Paclitaxel as Adjuvant Treatment for Papillary Serous and Clear Cell Endometrial Cancer. *International Journal of*

- Gynecological Cancer 2009;19(4):662-664.
22. Rose PG, Ali S, et al. Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma. *International Journal of Gynecological Cancer* 2017;27(3):452-458.
 23. Makker V, Rasco D, Nicholas NJ, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. *Lancet Oncol* 2019;20:711-718.
 24. Aghajanian C, Sill MW, Darcy KM, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. *J Clin Oncol* 2011;29:2259-2265.
 25. Moxley KM, McMeekin DS. Endometrial carcinoma: a review of chemotherapy, drug resistance, and the search for new agents. *Oncologist* 2010;15:1026-1033.
 26. Wadler S, Levy DE, Lincoln ST, et al. Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93. *J Clin Oncol* 2003;21:2110-2114.
 27. Muggia FM, Blessing JA, Sorosky J, Reid GC. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. *J Clin Oncol* 2002;20:2360-2364.
 28. Amanda N. Fader, Dana M. Roque, et al. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. *J Clin Oncol.* 2018;27:JCO2017765966.
 29. Geller MA, Ivy JJ, Ghebre R, et al. A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer. *Gynecol Oncol.* 2011;121(1):112-117.
 30. Azad NS, Gray RJ, Overman MJ, Schoenfeld JD, et al. Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. *J Clin Oncol.* 2020 Jan 20;38(3):214-222. doi: 10.1200/JCO.19.00818. Epub 2019 Nov 25. PMID: 31765263; PMCID: PMC6968795.
 31. Antill YC, Kok PS, Robledo K, et al. . Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: the phase II PHAEDRA trial (ANZGOG1601). *J Clin Oncol* 2019;37:5501-01. 10.1200/JCO.2019.37.15_suppl.5501
 32. Dhani NC, Hirte HW, Wang L, et al. Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86). *Clin Cancer Res.* 2020 Jun 1;26(11):2477-

2486. doi: 10.1158/1078-0432.CCR-19-2576. Epub 2020 Jan 28. PMID: 31992589; PMCID: PMC7269808.
33. Oza AM, Elit L, Tsao MS, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. *J Clin Oncol*. 2011;29(24):3278-3285.
34. O'Malley DM, Bariani GM, Cassier PA, et al. Pembrolizumab in patients with microsatellite Instability-high advanced endometrial cancer: Results from the KEYNOTE-158 study. *J Clin Oncol* 2022;40:752-761"
35. Grisham RN, Adaniel C, Hyman DM, et al. Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial Sloan-Kettering Cancer Center experience. *Int J Gynecol Cancer* 2012;22:807-11.
36. Vergote I, Powell MA, Teneriello MG, et al. Second-line lenvatinib in patients with recurrent endometrial cancer. *Gynecol Oncol* 2020;156:575-582.
37. Lee EK, Xiong N, Krasner C, et al. Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer. *Gynecol Oncol* 2025;198:1-8.
38. Schenker M, Burotto M, Richardet M, et al. Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden. *J Immunother Cancer* 2024;12:e008872.
39. Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumabderuxtecan in patients with HER2-expressing solid tumors: DESTINYPanTumor02 interim results. Presented at the American Society of Clinical Oncology Annual Meeting; June 2–6, 2023; Chicago, Illinois
40. Nishikawa T, Hasegawa K, Matsumoto K, et al. Trastuzumab deruxtecan for human epidermal growth factor receptor 2-expressing advanced or recurrent uterine carcinosarcoma (NCCH1615): The STATICE trial. *J Clin Oncol* 2023;41:2789-2799.
41. Subbiah V, Wolf J, Konda B, Kang H, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. *Lancet Oncol*. 2022 Oct;23(10):1261-1273.
42. Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. *Lancet Oncol*. 2020 Apr;21(4):531-540.
43. Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. *Lancet Oncol*. 2020 Feb;21(2):271-282.

Hormonal Therapy for Uterine-Limited Disease Not Suitable for Primary Surgery or for Those Desiring Uterine Preservation for Fertility

Preferred

- Levonorgestrel IUD

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Levonorgestrel IUD	52mg IMP		Q5Y		1

Other Recommended

- Continuous progestin-based therapy

Megestrol acetate

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Megestrol acetate	160mg PO		QD		2

Medroxyprogesterone acetate

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Medroxyprogesterone acetate	500 mg PO		QD		2

• Dual progestin agents

Levonorgestrel IUD/Megestrol acetate

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Levonorgestrel IUD	52mg IMP		Q5Y		3
Megestrol acetate	160mg PO		QD		

Levonorgestrel IUD/Medroxyprogesterone acetate

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Levonorgestrel IUD	52mg IMP		Q5Y		3
Medroxyprogesterone acetate	500mg PO		QD		

參考文獻

1. Westin SN, Fellman B, Sun CC, et al. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021 Feb;224(2):191.e1-191.e15. 15.
2. Park JY, Kim DY, Kim JH, et al. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002). Eur J Cancer 2013;49:868–874
3. Xu Z, Yang B, Guan J, Shan W, et al. Comparison of the effect of oral megestrol acetate with or without levonorgestrel-intrauterine system on fertility-preserving treatment in patients with early-stage endometrial cancer: a prospective, open-label, randomized controlled phase II trial (ClinicalTrials.gov NCT03241914). J Gynecol Oncol. 2023 Jan;34(1):e32.

《 卵巢癌抗癌藥物治療指引 》

115 年版與上一版差異

114 年版 修訂日 114/01/22	115 年版 修訂日 114/12/17
Chemotherapy as Primary or Adjuvant Therapy	Chemotherapy as Primary, Neoadjuvant, or Adjuvant Therapy ■ 新增 FOLFOX ± Bevacizumab ■ 新增 Hyperthermic intraperitoneal chemotherapy • Cisplatin/Paclitaxel/Carboplatin
Acceptable Recurrence Therapies First line therapy	Acceptable Recurrence Therapies ■ 刪除 First line therapy 標題 ■ 新增 Fam-trastuzumab deruxtecan ■ 新增 Mirvetuximab soravtansine ■ 新增 Mirvetuximab soravtansine + Bevacizumab ■ 新增 Larotrectinib ■ 新增 Entrectinib ■ 新增 Repotrectinib ■ 新增 Trametinib ± Dabrafenib ■ 新增 FOLFIRI + Bevacizumab

《 卵巢癌抗癌藥物治療指引 》

Chemotherapy as Primary, Neoadjuvant, or Adjuvant Therapy

IP/IV regimen

Paclitaxel + Cisplatin

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	135 IV	≥ 3 hrs	d1	Q3W	6	1
Cisplatin	75 IV / 100 IP	≥ 4 hrs	d2	Q3W	6	
Paclitaxel	60 IP		d8	Q3W	6	

Paclitaxel + Cisplatin

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 6 IP		d1	Q3W	6-8	17
Paclitaxel	80 IV	≥ 1 hr	d1, 8, 15	Q3W	6-8	

IV regimens

Paclitaxel + Carboplatin

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 6	1 hr	d1	Q3W	6	2
Paclitaxel	175	≥ 3 hrs	d1	Q3W	6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 6	1 hr	d1	Q3W	6	3
Paclitaxel	80	≥ 1 hr	d1, 8, 15	Q3W	6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 2	≥ 30 mins	d1	QW	18	8
Paclitaxel	60	≥ 1 hr	d1	QW	18	

Docetaxel + Carboplatin*

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Docetaxel	75	1 hr	d1	Q3W	6	4
Carboplatin	AUC 6	1 hr	d1	Q3W	6	

± maintenance letrozole (category 2B) or other hormonal therapy (category 2B) for Low-grade serous (stage IC)/Grade I endometrioid (stage IC)
Other hormonal therapy options include: aromatase inhibitors (anastrozole, exemestane), leuprolide acetate, or tamoxifen.

Carboplatin + Liposomal Doxorubicin*

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 5	1 hr	d1	Q4W	6	11
Lipo-Doxorubicin	30	2 hrs	d1	Q4W	6	

± maintenance letrozole (category 2B) or other hormonal therapy (category 2B) for Low-grade serous (stage IC)/Grade I endometrioid (stage IC)
Other hormonal therapy options include: aromatase inhibitors (anastrozole, exemestane), leuprolide acetate, or tamoxifen.

Paclitaxel + Carboplatin + Bevacizumab

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Bevacizumab	7.5 mg/kg	≥ 1 hr	d1	Q3W	6-12	5
Carboplatin	AUC 5 or 6	1 hr	d1	Q3W	6	
Paclitaxel	175	≥ 3 hrs	d1	Q3W	6	

Bevacizumab was initiated at cycle 2 to reduce the risk of wound-healing complications.

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Bevacizumab	15 mg/kg	≥ 1 hr	d1	Q3W	22*	6
Carboplatin	AUC 6	1 hr	d1	Q3W	6	
Paclitaxel	175	≥ 3 hrs	d1	Q3W	6	

Bevacizumab was initiated at cycle 2 to reduce the risk of wound-healing complications.

Docetaxel + Carboplatin + Bevacizumab

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Docetaxel	75	1 hr	d1	Q3W	6	18
Followed by Carboplatin	AUC 6	1 hr	d1	Q3W	1	
Followed by Bevacizumab	15 mg/kg	≥ 1 hr	d1	Q3W	21	
Carboplatin	AUC 6	1 hr	d1	Q3W	5	

PAC

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	50	≥ 3 hrs	d1	Q3W	6	7
Doxorubicin	50	≥ 30 mins	d1	Q3W	6	
Cyclophosphamide	500	30 mins	d1	Q3W	6	

PEC

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	60	≥ 3 hrs	d1	Q3W		9
Epirubicin	60	≥ 30 mins	d1	Q3W		
Cyclophosphamide	750	30 mins	d1	Q3W		

Paclitaxel followed by Cisplatin

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	175	≥ 3 hrs	d1	Q3W	3-9	19, 20
followed by Cisplatin	75	≥ 4 hrs	d1	Q3W	3-9	

FOLFOX ± Bevacizumab (For mucinous carcinoma)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Bevacizumab	5 mg/kg	≥ 1 hr	d1	Q2W		22
Oxaliplatin	85	2 hrs	d1	Q2W		
Leucovorin	400	≥ 90 mins	d1	Q2W		
5-FU (optional)	400	5 mins	d1	Q2W		
5-FU	1200	22-24 hrs	d1-2	Q2W		

Post Primary treatment- Maintenance PARP inhibitor

*newly diagnosed Stage II-IV or BCRA 1/2-mutated.

CR or PR is achieved after primary treatment with surgery and platinum-based 1st line.

1. Maintenance post primary chemotherapy +bevacizumab

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Bevacizumab	15 mg/kg	≥ 1 hr	d1	Q3W	For 15 months	13
Olaparib	300 mg BID PO				For 1 year	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Bevacizumab	15 mg/kg	≥ 1 hr	d1	Q3W	For 15 months	21
Niraparib	300 mg QD* PO				For 1 year	

*Or 200 mg QD for patients with a baseline body weight <77 kg, and/or PLT <150,000/mm³

2. Maintenance post primary chemotherapy

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Niraparib	300 mg QD* PO	d1	Q3W	For 36 months	14, 15

*Or 200 mg QD for patients with a baseline body weight <77 kg, and/or PLT <150,000/mm³

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Olaparib	300 mg BID PO				16

Malignant germ cell

BEP

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Bleomycin	20	30 mins	d1	Q3W	*	10
Cisplatin	20	2 hrs	d1-5	Q3W		
Etoposide	75	1 hr	d1-5	Q3W		

*3 cycles for good risk (category 2B), or 4 cycles for poor risk.

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Etoposide	120	1 hr	d1-3	Q4W	3	12
Carboplatin	AUC 5-6	1 hr	d1	Q4W	3	

Neoadjuvant Therapy

Paclitaxel + Carboplatin

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 6	1 hr	d1	Q3W	6	2
Paclitaxel	175	≥ 3 hrs	d1	Q3W	6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 2	≥ 30 mins	d1	QW	18	8
Paclitaxel	60	≥ 1 hr	d1	QW	18	

BEP

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Bleomycin	20	30 mins	d1	Q3W	*	10
Cisplatin	20	2 hrs	d1-5	Q3W		
Etoposide	75	1 hr	d1-5	Q3W		

*3 cycles for good risk (category 2B), or 4 cycles for poor risk.

Hyperthermic intraperitoneal chemotherapy

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Cisplatin	75-100	d1			23

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Paclitaxel	120	d1			24

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Carboplatin	800	d1			25

參考文獻

1. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. *N Engl J Med* 2006;354:34-43.
2. John K. Chan, Mark F. Brady, et al. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. *N Engl J Med* 2016; 374:738-748.
3. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. *Lancet* 2009;374:1331-1338.
4. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. *J Natl Cancer Inst* 2004;96:1682-1691.
5. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. *N Engl J Med* 2011;365:2484-2496.
6. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. *N Engl J Med* 2011;365:2473-2483.
7. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. *Lancet* 2002;360:505-515.
8. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. *Lancet* 2009;374:1331-1338.
9. Massacesi C1, Bascioni R, et al. Cisplatin, epirubicin and cyclophosphamide (PEC) in the treatment of advanced ovarian cancer. *J Exp Clin Cancer Res.* 2000 Mar;19(1):13-6.
10. Homesley HD, Bundy BN, Hurteau JA, Roth LM. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group study. *Gynecol Oncol.* 1999 Feb;72(2):131-7.
11. NCCN. [OV3 of 8] ovarian cancer: version 3, 2017.

12. Williams SD, Kauderer J, Burnett AF, Lentz SS, Aghajanian C, Armstrong DK. Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group. *Gynecol Oncol*. 2004;95(3):496-499.
13. Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. *N Engl J Med* 2019;381:2416-2428.
14. Gonzalez-Martin A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. *N Engl J Med* 2019;381:2391- 2402.
15. Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. *N Engl J Med* 2016;375:2154- 2164.
16. Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. *N Engl J Med* 2018;379:2495-2505.
17. Herzog TJ, Monk BJ, Rose PG, et al. A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. *Gynecol Oncol*. 2014 Mar;132(3):517-25. doi: 10.1016/j.ygyno.2014.01.035. Epub 2014 Jan 27. PMID: 24476788; PMCID: PMC5718618.
18. Tewari KS, Burger RA, Enserro D, et al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. *J Clin Oncol* 2019;37:2317-2328
19. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. *N Engl J Med* 1996;334:1-6
20. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin–paclitaxel versus cisplatin–cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. *J Natl cancer Inst* 2000;92:699-708.
21. Hardesty MM, Krivak TC, Wright GS, et al. OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab. *Gynecol Oncol* 2022;166:219-229
22. Sato S, Itamochi H, Kigawa J, Oishi T, , et al. Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy. *Cancer Sci*. 2009

- Mar;100(3):546-51.
23. Lim MC, Chang S-J, Yoo HJ, et al. Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer. 2017;35:5520- 5520.
 24. González Sánchez S, García Fernández J, et al. Interval Cytoreductive Surgery and Cisplatin- or Paclitaxel-Based HIPEC for Advanced Ovarian Cancer. JAMA Netw Open. 2025 Jun 2;8(6):e2517676.
 25. Zivanovic O, Chi DS, et al. Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study. J Clin Oncol. 2021 Aug 10;39(23):2594-2604.

Acceptable Recurrence Therapies

Platinum-Sensitive Disease

Preferred regimen

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	30 mins	d1, 8	Q3W	6 (Max 10)	1
Carboplatin	AUC 4	1 hr	d1	Q3W	6 (Max 10)	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Bevacizumab	15 mg/kg	≥ 1 hr	d1	Q3W	6 (Max 10)	2
Gemcitabine	1000	30 mins	d1, 8	Q3W	6 (Max 10)	
Carboplatin	AUC 4	1 hr	d1	Q3W	6 (Max 10)	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Bevacizumab	15 mg/kg	≥ 1 hr	d1	Q3W		18
Paclitaxel	175	≥ 3 hrs	d1	Q3W		
Carboplatin	AUC 5	1 hr	d1	Q3W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Bevacizumab	10 mg/kg	≥ 1 hr	d1, 15	Q4W	6	21
Lipo-Doxorubicin	30	2 hrs	d1	Q4W	6	
Carboplatin	AUC 5	1 hr	d1	Q3W	6	
Followed by						
Bevacizumab	10 mg/kg	≥ 1 hr	d1	Q3W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 5	1 hr	d1	Q4W	6	3
Lipo-Doxorubicin	30	2 hrs	d1	Q4W	6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 5	1 hr	d1	Q3W	6	4
Paclitaxel	175	≥ 3 hrs	d1	Q3W	6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 6	1 hr	d1	Q3W	6	5
Paclitaxel	80	≥ 1 hr	d1, 8, 15	Q3W	6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	750	30 mins	d1, 8	Q3W		6, 14
Cisplatin	30	≥ 1 hr	d1, 8	Q3W		

Other Recommended Regimens

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 2	≥ 30 mins	d1	QW	18	8
Paclitaxel	60	≥ 1 hr	d1	QW	18	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cisplatin	75	≥ 4 hrs	d1	Q3W	6	4

Useful in Certain Circumstances

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W		22

MSI-H, or dMMR, or TMB-H

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Dostarlimab-gxly	500 mg	≥ 30 mins	d1	Q3W	4	23
followed by Dostarlimab-gxly	1000 mg	≥ 30 mins	d1	Q6W		

MSI-H

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Selpercatinib	160 mg BID PO				24

for RET gene fusion-positive tumor

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Repotrectinib	160 mg PO QD	d1-14			24
	160 mg PO BID	d15 and after			

for NTRK gene fusion-positive tumors

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Larotrectinib	100mg PO		QD		24

for NTRK gene fusion-positive tumors

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Entrectinib	600 mg PO		QD		24

for NTRK gene fusion-positive tumors

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Fam-trastuzumab deruxtecan-nxki	5.4mg/kg	90 mins	d1	Q3W		35

HER2-positive tumors (IHC 3+ or 2+)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Mirvetuximab soravtansine-gynx	6mg/kg	1 → 3 → 5 mg/min	d1	Q3W		37

FR α -expressing tumors $\geq$ 75% positive tumor cells

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Mirvetuximab soravtansine-gynx	6mg/kg	1 → 3 → 5 mg/min	d1	Q3W		38
bevacizumab	15mg/kg	$\geq$ 1 hr	d1	Q3W		

FR α -expressing tumors $\geq$ 50% positive tumor cells

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Dabrafenib	150mg PO		BID		39
Trametinib	2mg PO		QD		

for BRAF V600E-positive tumors

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Trametinib	2mg PO		QD		40

For low-grade serous carcinoma

Platinum-Resistant Disease

(Platinum agents have limited activity when the disease has demonstrated growth through a platinum-based regimen, and platinum rechallenge is generally not recommended in this setting)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 5-6	1 hr	d1	Q3W		25

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Docetaxel	75	1 hr	d1	Q3W	6	26
Followed by Carboplatin	AUC 5	1 hr	d1	Q3W	6	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
± Bevacizumab	15 mg/kg	≥ 1 hr	d1	Q3W	6 (Max 10)	2
Gemcitabine	1000	30 mins	d1, 8	Q3W	6 (Max 10)	
Carboplatin	AUC 4	1 hr	d1	Q3W	6 (Max 10)	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 2	≥ 30 mins	d1	QW	18	27, 28
Paclitaxel	60	≥ 1 hr	d1	QW	18	

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Bevacizumab	10 mg/kg	≥ 1 hr	d1, 15	Q4W	6	29
Lipo-Doxorubicin	30	2 hrs	d1	Q4W	6	
Carboplatin	AUC 5	1 hr	d1	Q4W	6	
Followed by Bevacizumab	15 mg/kg	≥ 1 hr	d1	Q3W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
± Bevacizumab	15 mg/kg	≥ 1 hr	d1	Q3W		18
Carboplatin	AUC 4	1 hr	d1	Q3W		
Paclitaxel	175	≥ 3 hrs	d1	Q3W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Bevacizumab	15 mg/kg	≥ 1 hr	d1	Q3W		30
Gemcitabine	1000	30 mins	d1, 8	Q3W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	30 mins	d1, 8	Q3W		6, 14
Cisplatin	30	≥ 1 hr	d1, 8	Q3W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Ixabepilone	20	30 mins	d1, 8, 15	Q4W		31
Bevacizumab	10 mg/kg	≥ 1 hr	d1, 15	Q4W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Cyclophosphamide	50 mg PO QD	30 mins				32, 33
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W		
Bevacizumab	15 mg/kg	≥ 1 hr	d1	Q3W		

Weekly Paclitaxel ± Pazopanib

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Paclitaxel	80	≥ 1 hr	d1	QW		15
± Pazopanib	800 mg PO QD					

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Bevacizumab	10 mg/kg	≥ 1 hr	d1	QW		15
Paclitaxel	80	≥ 1 hr	d1	QW		

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	d1, 8	Q3W		7

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	d1, 8, 15	Q4W		8

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Lipo-Doxorubicin	40 or 50	2 hrs	d1	Q4W		7, 8

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Bevacizumab	10 mg/kg	≥ 1 hr	d1, 15	Q4W		9
Lipo-Doxorubicin	40	2 hrs	d1	Q4W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Topotecan	1.25 or 1.5	1 hr	d1-5	Q3W		10, 11

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Topotecan	4	1 hr	d1, 8, 15	Q4W		11

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Bevacizumab	15 mg/kg	≥ 1 hr	d1	Q3W		9
Topotecan	1.25	1 hr	d1-5	Q3W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Bevacizumab	10 mg/kg	≥ 1 hr	d1, 15	Q4W		9
Topotecan	4	1 hr	d1, 8, 15	Q4W		

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Bevacizumab	15 mg/kg	≥ 1 hr	d1	Q3W		12, 13

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Bevacizumab	10 mg/kg	≥ 1 hr	d1	Q2W		20

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Docetaxel	100	1 hr	d1	Q3W		17

Oral Etoposide

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Etoposide	50-60* PO	d1-21	Q4W		19

*reduced to 30 mg/m2/day for prior radiotherapy

Useful in Certain Circumstances

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W		22

MSI-H, or dMMR, or TMB-H

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Dostarlimab-gxly	500 mg	30 mins	d1	Q3W	4	23
followed by Dostarlimab-gxly	1000 mg	30 mins	d1	Q6W		

MSI-H

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Fam-trastuzumab deruxtecan-nxki	5.4 mg/kg	90 mins	d1	Q3W		34

for HER2-positive tumors [IHC 3+ or 2+]

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Selpercatinib	160 mg PO		BID		24

for RET gene fusion-positive tumor

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Larotrectinib	100mg PO		QD		24

for NTRK gene fusion-positive tumors

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Entrectinib	600 mg PO		QD		24

for NTRK gene fusion-positive tumors

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Repotrectinib	160 mg PO QD	d1-14			24
	160 mg PO BID	d15 and after			

for NTRK gene fusion-positive tumors

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Mirvetuximab soravtansine-gynx	6mg/kg	1 → 3 → 5 mg/min	d1	Q3W		37

FR α -expressing tumors $\geq$ 75% positive tumor cells

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Mirvetuximab soravtansine-gynx	6mg/kg	1 → 3 → 5 mg/min	d1	Q3W		38
bevacizumab	15mg/kg	≥ 1 hr	d1	Q3W		

FR α -expressing tumors ≥ 50% positive tumor cells

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Dabrafenib	150mg PO		BID		39
Trametinib	2mg PO		QD		

For BRAF V600E-positive tumors

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Trametinib	2mg PO		QD		40

For low-grade serous carcinoma

FOLFIRI + Bevacizumab (For mucinous carcinoma)

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Bevacizumab	5 mg/kg	≥ 1 hr	d1	Q2W		36
Irinotecan	180	≥ 90 mins	d1	Q2W		
Leucovorin	400	≥ 90 mins	d1	Q2W		
5-FU (optional)	400	5 mins	d1	Q2W		
5-FU	1200	22-24 hrs	d1-2	Q2W		

參考文獻

1. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. *J Clin Oncol* 2006;24:4699-4707.
2. Aghajanian C, Blank SV, Goff BA, et al. A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. *J Clin Oncol* 2012;30:2039-2045.
3. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse. *J Clin Oncol* 2010;28:3323-3329.
4. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. *Lancet* 2003;361:2099-2106.
5. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. *Lancet* 2009;374:1331-1338.
6. Rose PG. Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma. *Int J Gynecol Cancer* 2005;15:18-22.
7. Mutch DG, Orlando M, Goss T, et al. Randomized Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer. *J Clin Oncol* 2007;25:2811-2818.
8. Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian Cancer. *J Clin Oncol* 2008;26:890-896.
9. Pujade-Lauraine E, Hilpert F, Wener B, et al. Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial. *J Clin Oncol* 2014;32(13):1302-1308.
10. Gordon AN, Tonda M, Sun S, Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. *Gynecol Oncol* 2004;95:1-8.

11. Sehouli J, Stengel D, Harter P, et al. Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. *J Clin Oncol* 2011;29:242-248.
12. Burger RA, Sill MW, Monk BJ, et al. Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study. *J Clin Oncol* 2007;25:5165-5171.
13. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer. *J Clin Oncol* 2007;25:5180-5186.
14. Rose PG, Mossbruger K, Fusco N, Smrekar M, Eaton S, Rodriguez M. Gemcitabine reverses Cisplatin resistance: demonstration of activity in Platinum and multidrug-resistant ovarian and peritoneal carcinoma. *Gynecol Oncol* 2003; 88: 17–21.
15. Pignata S, Sandro D, Scambia G et al. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. *Lancet Oncol* 2015; 16:561-568.
16. Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation. *J Clin Oncol* 2015;33:244-250.
17. Rose PG, Blessing JA, Ball HG, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol.* 2003;88(2):130-5.
18. Coleman RL, Brady MF, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol.* 2017 Jun;18(6):779-791.
19. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol.* 1998;16(2):405-410.
20. Luigi Rossi, Monica Verrico, Eleonora Zaccarelli, et al. Bevacizumab in ovarian cancer: A critical review of phase III studies. *Oncotarget.* 2017 Feb 14; 8(7): 12389–12405.
21. Carboplatin/pegylated liposomal Doxorubicin/Bevacizumab (CD-BEV) vs. Carboplatin/Gemcitabine/Bevacizumab (CG-BEV) in patients with recurrent ovaria. A prospective randomized phase III ENGOT/GCIG-Intergroup study (AGO Study Group, AGO-Austra, ANZGOG, GINECO, SGCTG). *ESMO Congress* 2018; Munch, Germany. Abstract 9330.

22. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science* 2017;357:409-413.
23. Berton D, Banerjee S, Curigliano G, et al. Antitumor activity of dostarlimab in patients with mismatch repair-deficient (dMMR) tumors: a combined analysis of 2 cohorts in the GARNET study. Poster presented at American Society for Clinical Oncology (ASCO), Virtual Meeting, June 4–8, 2021. [Abstract ID: 2564].
24. Subbiah V, Wolf J, Konda B, et al. Tumour agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid: a global, phase 1/2, multicentre, open-label trial (LIBRETTO-001). *Lancet Oncol* 2022;23:1261-1273.
25. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.
26. Strauss HG, Henze A, Teichmann A, et al. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer. *Gynecol Oncol* 2007;104:612-616. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17069876>.
27. Blagden SP, Cook AD, Poole C, et al. Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. *Lancet Oncol* 2020;21:969-977. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32615110>.
28. Clamp AR, James EC, McNeish IA, et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. *Lancet* 2019;394:2084-2095. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31791688>.
29. Pfisterer J, Shannon CM, Baumann K, et al. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2020 May;21(5):699-709. doi: 10.1016/S1470-2045(20)30142-X. Epub 2020 Apr 16. Erratum in: *Lancet Oncol*. 2022 Jun;23(6):e248. PMID: 32305099.
30. Nagao S, Kogiku A, Suzuki K, et al. A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. *J Ovarian Res* 2020;13:14.

31. Roque DM, Siegel E, Buza N, et al. Randomised phase II trial of weekly ixabepilone ±biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. *Br J Cancer* 2022;126:1695–1703.
32. Zsiros E, Lynam S, Attwood KM, et al. Efficacy and safety of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer: A phase 2 nonrandomized clinical trial. *JAMA Oncol* 2021;7:78-85.
33. Poblete S, Caulkins M, Loecher C, et al. Pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: Real-life clinical experience [abstract]. *Ann Oncol* 2022;33(Suppl): Abstract 569P.
34. Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial. *J Clin Oncol* 2024;42:47-58.
35. Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial. *J Clin Oncol* 2024;42:47-58.
36. Kurnit CK, Sinno AK, Fellman BM, et al. Effects of gastrointestinal-type chemotherapy in women with ovarian mucinous carcinoma. *Obstet Gyn* 2019;134:1253-1259.
37. Secord AA, Lewin SN, Murphy CG, Cecere SC, et al. The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single Arm Phase 2 PICCOLO Trial. *Ann Oncol*. 2024:S0923-7534:04948-2.
38. Gilbert L, Oaknin A, Matulonis UA, et al. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. *Gynecol Oncol* 2023;170:241-247.
39. Salama A, Li S, Macrae E, et al. Dabrafenib and trametinib in patients with tumors with BRAF V600E mutations: Results of the NCI-MATCH trial subprotocol H. *J Clin Oncol* 2020;38:3895-3904
40. Gershenson DM, Miller A, Brady W, et al. A randomized phase II/III study to assess the efficacy of trametinib in patients with recurrent or progressive low-grade serous ovarian or peritoneal cancer [abstract]. *Ann Oncol* 2019;30(Suppl):V897-V898.

Targeted Therapy for Recurrence Disease

藥品名	劑量 mg/m ²	輸注時間	給藥日	頻率	週期	參考文獻
Bevacizumab	15 mg/kg	≥ 1 hr	d1	Q3W		1
Niraparib	300 mg* PO			QD		

*Or 200 mg QD for patients with a baseline body weight <77 kg, and/or PLT <150,000/mm For platinum-sensitive

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Niraparib	300 mg* PO			QD	2

*Or 200 mg QD for patients with a baseline body weight <77 kg, and/or PLT <150,000/mm

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Olaparib	300 mg		BID		3

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Pazopanib	800 mg		QD		4

Hormone Therapy for Recurrence Disease

Aromatase inhibitor

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Exemestane	25 mg PO		QD		7

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Anastrozole	1 mg PO		QD		5

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Letrozole	2.5 mg PO		QD		6

Ovarian suppression or ablation

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Goserelin Acetate*	3.6 mg SC	1	Q4W		10

*or 10.8mg SC Q3M

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Leuprolide Acetate*	3.75 mg SC	1	Q4W		8

* 11.25 mg SC Q3M

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Megestrol acetate	160mg PO		QD		11

Anti-estrogen

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Tamoxifen	20 mg PO		QD		9

參考文獻

1. Mirza MR, Avall Lundqvist E, Birrer MJ, et al. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGOAVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. *Lancet Oncol* 2019;20:1409-1419.
2. Moore KN, Secord AA, Geller MA, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. *Lancet Oncol* 2019;20:636-648.
3. Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. *J Clin Oncol* 2015;33:244-250.
4. Friedlander M, Hancock KC, Rischin D, et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. *Gynecol Oncol* 2010;119:32-37.
5. Anastrozole [package insert]. AstraZeneca Pharmaceuticals LP
6. Letrozole [package insert]. Novartis Pharmaceuticals Corporation
7. Exemestane [package insert]. Pfizer Inc.
8. Leuprolide acetate [package insert]. AbbVie Inc.
9. Tamoxifen citrate [package insert]. AstraZeneca Pharmaceuticals LP
10. Goserelin acetate [package insert]. AstraZeneca Pharmaceuticals LP
11. Belinson JL, McClure M, Badger G. Randomized trial of megestrol acetate vs. megestrol acetate/tamoxifen for the management of progressive or recurrent epithelial ovarian carcinoma. *Gynecol Oncol.* 1987 Oct;28(2):151-5. doi: 10.1016/0090-8258(87)90208-3. PMID: 3311923.